SCHEMBL10880239

SCHEMBL10880239

CCOc1cccc(N)c1C(N)=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
HSD17B10 Q99714 3/20 0.46
NPC1 O15118 1/20 0.46
USP2 O75604 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
GLA P06280 1/20 0.46
CREBBP Q92793 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 2/20 0.44
PARP10 Q53GL7 1/20 0.43
LMNA P02545 1/20 0.42
MCL1 Q07820 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GAA P10253 2/20 0.42
HCRTR1 O43613 1/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16666142 0.89 GLA (0.52) ALDH1A1L3MBTL1GLATSHRMAPK1
SCHEMBL11453393 0.87 CYP1A2 (0.49) ALDH1A1HSD17B10NPC1USP2RAB9A
SCHEMBL6469761 0.86 ALDH1A1 (0.56) ALDH1A1HSD17B10NPC1USP2RAB9A
SCHEMBL11445471 0.85 CYP1A2 (0.60) ALDH1A1HSD17B10TSHRLMNAGAA
SCHEMBL3983602 0.83 ALDH1A1 (0.53) ALDH1A1HSD17B10NPC1USP2RAB9A
SCHEMBL28125927 0.83 ALDH1A1 (0.53) ALDH1A1HSD17B10NPC1USP2RAB9A
SCHEMBL4696202 0.83 MAPK1 (0.55) ALDH1A1SMN1; SMN2L3MBTL1GLATSHR
SCHEMBL28192820 0.83 MEN1 (0.50) L3MBTL1GLATSHRMAPK1PARP10
SCHEMBL12194458 0.82 ALDH1A1 (0.36) ALDH1A1HSD17B10USP2SMN1; SMN2LMNA
SCHEMBL11445469 0.81 TBXAS1 (0.39) ALDH1A1SMN1; SMN2LMNAGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360085-A1 Glucose Uptake Inhibitors KADMON CORPORATION, LLC (US) 2024-10-31 US disclosed
US-12030857-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2024-07-09 US disclosed
US-12030857-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2024-07-09 US disclosed
US-12030857-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2024-07-09 US disclosed
US-20220363648-A1 Glucose Uptake Inhibitors KADMON CORPORATION, LLC 2022-11-17 US disclosed
EP-0065811-B1 DISPERSE AZOPYRIMIDINE DYESTUFFS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1986-01-02 EP disclosed
EP-0065811-A1 Disperse azopyrimidine dyestuffs IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1982-12-01 EP disclosed
US-4191840-A Oxamic acid derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 1980-03-04 US disclosed
US-4160100-A OXAMIC ACID DERIVATIVES AMERICAN HOME PRODUCTS CORPORATION (US) 1979-07-03 US disclosed
US-4154961-A Oxamic acid derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 1979-05-15 US disclosed
US-4069343-A OXAMIC ACID DERIVATIVES FOR THE PREVENTION OF IMMEDIATE TYPE HYPERSENSITIVITY REACTIONS AMERICAN HOME PRODUCTS CORPORATION (US) 1978-01-17 US disclosed
US-4054661-A Pyridyl oxamic acid derivatives and use in the prevention of allergic reactions AMERICAN HOME PRODUCTS CORPORATION (US) 1977-10-18 US disclosed
US-4054657-A Pyrimidinyl oxamic acids and esters, and compositions and methods for the suppression of allergic manifestations AMERICAN HOME PRODUCTS CORPORATION (US) 1977-10-18 US disclosed
US-4054666-A Compositions and methods of treating immediate hypersensitivity reactions with thiazolyl oxamic acid derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 1977-10-18 US disclosed
US-4036837-A 2 Alkoxyoxamoyl-pyrazines AMERICAN HOME PRODUCTS CORPORATION (US) 1977-07-19 US disclosed
US-3966965-A Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions AMERICAN HOME PRODUCTS CORPORATION (US) 1976-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030857-B2 Glucose uptake inhibitors SLC2A1, SLC2A4, SLC2A2 ALDH1A1 1422/4885HSD17B10 749/4885NPC1 201/4885
US-20220363648-A1 Glucose Uptake Inhibitors SLC2A1, SLC2A4, SLC2A2 ALDH1A1 1422/4885HSD17B10 749/4885NPC1 201/4885
US-20240360085-A1 Glucose Uptake Inhibitors SLC2A3, SLC2A1, SLC2A4 ALDH1A1 1565/4885HSD17B10 806/4885NPC1 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.